GlaxoSmithKline poached Pfizer’s key vaccine executives as British pharmaceutical companies are making big bets in the future. mRNA technology..
Philip Dormitzer This week, he is leaving the company that played a key role in the development of Pfizer’s Covid-19 vaccine, including joining GSK as Global Head of Vaccine Research and Development and helping build partnerships with BioNTech.
He led the virus vaccine portfolio of a US pharmaceutical company, including BioNTech’s research on influenza mRNA vaccines, and oversaw vaccine candidates for respiratory syncytial virus that compete with Shot, which is being developed by GSK. Pfizer did not respond to requests for comment.
Halbaron, GSK’s Chief Scientific Officer, said he was “willing” to welcome Dormitzer with his “significant experience” in mRNA and other technologies, and employment is the key to maintaining GSK. Said there is. Vaccine leader..
“The importance of vaccines has become clearer than ever, and the pace of innovation has rarely increased,” he said.
GSK has Late At the Covid Jab race. Instead of designing it on its own, we provided an “immude” to increase the efficacy of a variety of other vaccines, including a vaccine developed by the French pharmaceutical company Sanofi. However, Retreat in previous trial, Sanofi and GSK have not yet produced Phase 3 results for vaccine candidates.
UK pharmaceutical companies are investing heavily in mRNA technology, including a second-generation Covidshot partnership with the German biotechnology CureVac.
GSK CEO Dame Emma Walmsley faced a question about the lack of scientific expertise. Revitalize the company’s pharmaceutical pipeline..Activist investor Elliott Management Bluebird Capital Partners has invested to drive a faster transformation of the Group ahead of the upcoming spin-off of the consumer health business next year.
Dormitzer helps strengthen GSK’s top science team and shows that GSK is working on vaccine innovation. Senior vaccine executives have left GSK to join small businesses this year, including Amin Khan, who attended GreenLight Biosciences, Emmanuel Hanon, who joined Viome, and Amir Reichman, who now heads BiondVax Pharmaceuticals.
Roger Connor, president of GSK’s Global Vaccines, told the Financial Times that the pandemic helped prove the value of mRNA technology.
“We are making a huge investment behind this. There are 200 scientists working on mRNA, but not CureVac scientists. [and] We are building the capacity to produce mRNA vaccines, “he said.
GSK Announces Pfizer’s Leading Vaccine Executives
Source link GSK Announces Pfizer’s Leading Vaccine Executives